港股药捷安康-B（02617）今日盘中大跌5.02%，引发市场关注。该公司此前刚刚宣布将被纳入多个恒生指数系列成份股，但股价却出现大幅下跌。
根据公司公告，药捷安康-B将于2025年9月8日起被纳入恒生综合指数、恒生医疗保健指数、恒生创新药指数等多个恒生指数系列。这一消息本应利好公司股价，但投资者似乎并未对此作出积极反应。
另一方面，药捷安康-B近日公布了截至2025年6月底的中期业绩。报告显示，公司亏损收窄至1.23亿元人民币，较去年同期的1.6亿元有所改善。然而，公司仍未产生收入，这可能引发了投资者对其未来盈利能力的担忧。分析人士认为，尽管公司被纳入重要指数，但其当前的财务状况可能不及市场预期，导致股价出现较大幅度的调整。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.